Prognostic Value of Dysmyelopoiesis in 128 Patients with De Novo Acute Myeloid Leukemia

In a prospective setting we investigated several cytomorphological features in 128 patients with de novo acute myeloid leukemia (AML) treated in the AML cooperative Group (CG)-92 trial. The most important question to be answered was whether or not dysplasia had a prognostic impact for the remission rate and survival in AML. We could demonstrate a significantly lower remission rate for patients with trilineage dysplasia (TLD) in comparison to those without any dysplastic features. The overall survival was worse for patients with TLD as well but this was not statistically significant at the time of this analysis. Further investigations will help to define new risk factors as a result of this detailed analysis of bone marrow morphology.